Lilly, Merck and Pfizer have joined in a precompetitive deal to study the pharmacogenomics of Asian cancer patients. They expect to triple the power of the resulting open-source database at a third of the cost to each company. However, drug discovery itself will remain within the competitive confines of each pharma.